Astrana Health, Inc. Reports Third Quarter 2024 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/22/2026

1. WMT
2. ROST
3. AAP
4. NVDA
5. SPY
6. AVGO
7. SPCX
8. BJ
9. BABA
10. DE

November 7, 2024 4:36 PM EST

Company to Host Conference Call on Thursday, November 7, 2024, at 2:30 p.m. PT/5:30 p.m. ET

ALHAMBRA, Calif., Nov. 7, 2024 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a leading provider-centric, technology-powered healthcare company enabling providers to deliver accessible, high-quality, and high-value care to all, today announced its consolidated financial results for the third quarter ended September 30, 2024.

"Astrana's strong third quarter continues to reflect the outcomes we are driving with the Astrana care model and value-based care enablement platform. We continued to see strong organic and inorganic growth across our businesses while delivering high-quality care and managing costs effectively in the quarter. We are confident in our platform's ability to continue improving access, quality, and coordination of care for around 1.1 million patients in local communities nationwide," said President and CEO of Astrana, Brandon K. Sim.

Financial Highlights for three months ended September 30, 2024:

All comparisons are to the three months ended September 30, 2023 unless otherwise stated.

  • Total revenue of $478.7 million, up 37% from $348.2 million
  • Care Partners revenue of $455.8 million, up 42% from $320.9 million
  • Net income attributable to Astrana of $16.1 million, down 27% from $22.1 million
  • Earnings per share - diluted ("EPS - diluted") of $0.33, down 30% from $0.47
  • Adjusted EBITDA of $45.2 million, down 13% from $52.0 million

Financial Highlights for the nine months ended September 30, 2024:

All comparisons are to the nine months ended September 30, 2023 unless otherwise stated.

  • Total revenue of $1,369.3 million, up 32% from $1,033.6 million
  • Care Partners revenue of $1,301.4 million, up 36% from $957.3 million
  • Net income attributable to Astrana of $50.1 million, up 4% from $48.4 million
  • Earnings per share - diluted ("EPS - diluted") of $1.04, up 1% from $1.03
  • Adjusted EBITDA of $135.3 million, up 15% from $117.6 million

Recent Operating Highlights

  • On October 4, 2024, the Company closed the acquisition of all of the outstanding membership interest in Collaborative Health Systems, LLC ("CHS") and all of the outstanding equity interests in Golden Triangle Physician Alliance and Heritage Physician Networks for an aggregate purchase price of $37.5 million, subject to customary adjustments, plus earnout payments in an aggregate amount of up to $21.5 million.

Segment Results for three months ended September 30, 2024:




Three Months Ended September 30, 2024


(in thousands)


Care
Partners



Care
Delivery



Care
Enablement



Other



Intersegment
Elimination




Corporate
Costs



Consolidated
Total


Total revenues


$

455,760



$

34,728



$

40,930



$

—



$

(52,708)




$

—



$

478,710


% change vs. prior year quarter



42

%



20

%



11

%





































Cost of services



369,835




29,114




19,604




—




(13,335)





—




405,218


General and administrative(1)



47,139




6,971




15,012




—




(39,370)





15,315




45,067


Total expenses



416,974




36,085




34,616




—




(52,705)





15,315




450,285

























Income (loss) from operations


$

38,786



$

(1,357)



$

6,314



$

—



$

(3)


(2)


$

(15,315)



$

28,425


% change vs. prior year quarter



(4)

%



31

%



(2)

%














(1)

Balance includes general and administrative expenses and depreciation and amortization.

(2)

Income from operations for the intersegment elimination represents rental income from segments renting from other segments. Rental income is presented within other income which is not presented in the table.

2024 Guidance:

As we adjust our full-year outlook to incorporate CHS's financial contribution, we are raising our revenue guidance and narrowing our net income attributable to Astrana, Adjusted EBITDA, and EPS guidance for the year ending December 31, 2024.

($ in millions, except per share amounts)


2024 Guidance Range




Low



High


Total revenue


$

1,950



$

2,030


Net income attributable to Astrana Health, Inc.


$

52



$

58


Adjusted EBITDA


$

165



$

175


EPS – diluted


$

1.06



$

1.19


See "Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA" and "Use of Non-GAAP Financial Measures" below for additional information. There can be no assurance that actual amounts will not be materially higher or lower than these expectations. See "Forward-Looking Statements" below for additional information.

Conference Call and Webcast Information:

Astrana will host a conference call at 2:30 p.m. PT/5:30 p.m. ET today (Thursday, November 7, 2024), during which management will discuss the results of the third quarter ended September 30, 2024. To participate in the conference call, please use the following dial-in numbers about 5 minutes prior to the scheduled conference call time:

U.S. & Canada (Toll-Free):       +1 (888) 272-8703
International (Toll):                   +1 (713) 481-1320

The conference call can also be accessed via webcast at: https://event.choruscall.com/mediaframe/webcast.html?webcastid=qeu83NWd

An accompanying slide presentation will be available in PDF format on the "IR Calendar" page of the Company's website (https://ir.astranahealth.com/news-events/ir-calendar) after issuance of the earnings release and will be furnished as an exhibit to Astrana's current report on Form 8-K to be filed with the SEC, accessible at www.sec.gov.

Those who are unable to attend the live conference call may access the recording at the above webcast link, which will be made available shortly after the conclusion of the call.

Note About Consolidated Entities

The Company consolidates entities in which it has a controlling financial interest. The Company consolidates subsidiaries in which it holds, directly or indirectly, more than 50% of the voting rights, and variable interest entities ("VIEs") in which the Company is the primary beneficiary. Noncontrolling interests represent third party equity ownership interests in the Company's consolidated entities (including certain VIEs). The amount of net income attributable to noncontrolling interests is disclosed in the Company's consolidated statements of income.

Note About Stockholders' Equity, Certain Treasury Stock and Earnings Per Share

As of the date of this press release, 41,048 holdback shares have not been issued to certain former shareholders of the Company's subsidiary, Astrana Health Management, Inc. ("AHM"), formerly known as Network Medical Management, Inc., who were AHM shareholders at the time of closing of the merger, as they have yet to submit properly completed letters of transmittal to Astrana in order to receive their pro rata portion of Astrana's common stock and warrants as contemplated under that certain Agreement and Plan of Merger, dated December 21, 2016, among Astrana, AHM, Apollo Acquisition Corp. ("Merger Subsidiary") and Kenneth Sim, M.D., as amended, pursuant to which Merger Subsidiary merged with and into AHM, with AHM as the surviving corporation. Pending such receipt, such former AHM shareholders have the right to receive, without interest, their pro rata share of dividends or distributions with a record date after the effectiveness of the merger. The Company's consolidated financial statements have treated such shares of common stock as outstanding, given the receipt of the letter of transmittal is considered perfunctory and Astrana is legally obligated to issue these shares in connection with the merger.

Shares of Astrana's common stock owned by Allied Physicians of California, a Professional Medical Corporation ("APC"), a VIE of the Company, are legally issued and outstanding but excluded from shares of common stock outstanding in the Company's consolidated financial statements, as such shares are treated as treasury shares for accounting purposes. Such shares, therefore, are not included in the number of shares of common stock outstanding used to calculate the Company's earnings per share.

About Astrana Health,  Inc.

Astrana is a leading physician-centric, technology-powered, risk-bearing healthcare management company. Leveraging its proprietary population health management and healthcare delivery platform, Astrana operates an integrated, value-based healthcare model, which aims to empower the providers in its network to deliver the highest quality of care to its patients in a cost-effective manner. Together with our affiliated physician groups and consolidated entities, we provide coordinated outcomes-based medical care in a cost-effective manner.

Headquartered in Alhambra, California, Astrana serves over 12,000 providers and approximately 1.1 million patients in value-based care arrangements. Its subsidiaries and affiliates include management services organizations (MSOs), a network of risk-bearing organizations ("RBOs") that encompasses independent practice associations ("IPAs"), accountable care organizations ("ACOs"), and state-specific entities such as Restricted Knox-Keene licensed health plans in California, and care delivery entities across primary, multi-specialty, and ancillary care. For more information, please visit www.astranahealth.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements about the Company's guidance for the year ending December 31, 2024, ability to meet operational goals, ability to meet expectations in deployment of care coordination and management capabilities, ability to decrease cost of care while improving quality and outcomes, ability to deliver sustainable revenue and EBITDA growth as well as long-term value, ability to respond to the changing environment, and successful implementation of strategic growth plans, acquisition strategy, and merger integration efforts. Forward-looking statements reflect current views with respect to future events and financial performance and therefore cannot be guaranteed. Such statements are based on the current expectations and certain assumptions of the Company's management, and some or all of such expectations and assumptions may not materialize or may vary significantly from actual results. Actual results may also vary materially from forward-looking statements due to risks, uncertainties and other factors, known and unknown, including the risk factors described from time to time in the Company's reports filed or furnished with the Securities and Exchange Commission, including, without limitation the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and any subsequent quarterly reports on Form 10-Q.

FOR MORE INFORMATION, PLEASE CONTACT:

Investor Relations
(626) 943-6491
[email protected]

ASTRANA HEALTH, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(IN THOUSANDS, EXCEPT SHARE AND PER SHARE DATA)



September 30,
2024



December 31,
2023




(Unaudited)





Assets














Current assets







Cash and cash equivalents


$

347,994



$

293,807


Investment in marketable securities



2,354




2,498


Receivables, net



132,237




76,780


Receivables, net – related parties



76,568




58,980


Income taxes receivable



16,211




10,657


Other receivables



1,120




1,335


Prepaid expenses and other current assets



20,506




17,450









Total current assets



596,990




461,507









Non-current assets







Land, property and equipment, net



12,172




7,171


Intangible assets, net



109,108




71,648


Goodwill



409,711




278,831


Income taxes receivable



15,943




15,943


Loans receivable, non-current



55,284




26,473


Investments in other entities – equity method



34,629




25,774


Investments in privately held entities



8,896




6,396


Restricted cash



646




345


Operating lease right-of-use assets



33,119




37,396


Other assets



8,878




1,877









Total non-current assets



688,386




471,854









Total assets(1)


$

1,285,376



$

933,361









Liabilities, mezzanine equity and equity














Current liabilities







Accounts payable and accrued expenses


$

94,811



$

59,949


Fiduciary accounts payable



6,041




7,737


Medical liabilities



160,279




106,657


Dividend payable



638




638


Finance lease liabilities



554




646


Operating lease liabilities



5,241




4,607


Current portion of long-term debt



15,000




19,500


Other liabilities



30,364




18,940









Total current liabilities



312,928




218,674









Non-current liabilities







Deferred tax liability



2,857




4,072


Finance lease liabilities, net of current portion



743




1,033


Operating lease liabilities, net of current portion



31,162




36,289


Long-term debt, net of current portion and deferred financing costs



423,119




258,939


Other long-term liabilities



7,460




3,586









Total non-current liabilities



465,341




303,919









Total liabilities(1)



778,269




522,593









Commitments and contingencies














Mezzanine equity







Noncontrolling interest in Allied Physicians of California, a Professional Medical Corporation ("APC")



(202,512)




(205,883)









Stockholders' equity







Preferred stock, $0.001 par value per share; 5,000,000 shares authorized as of
September 30, 2024 and December 31, 2023







Series A Preferred stock, zero authorized and issued and zero outstanding as of
September 30, 2024 and 1,111,111 authorized and issued and zero outstanding as of
December 31, 2023



—




—


Series B Preferred stock, zero authorized and issued and zero outstanding as of
September 30, 2024 and 555,555 authorized and issued and zero outstanding as of
December 31, 2023



—




—


Common stock, $0.001 par value per share; 100,000,000 shares authorized,
47,780,523 and 46,843,743 shares issued and outstanding, excluding 10,598,749
and 10,584,340 treasury shares, as of September 30, 2024 and December 31, 2023,
respectively



48




47


Additional paid-in capital



411,334




371,037


Retained earnings



293,234




243,134


Total stockholders' equity



704,616




614,218









Non-controlling interest



5,003




2,433









Total equity



709,619




616,651









Total liabilities, mezzanine equity and equity


$

1,285,376



$

933,361


(1)

The Company's condensed consolidated balance sheets include the assets and liabilities of its consolidated VIEs. The condensed consolidated balance sheets include total assets that can be used only to settle obligations of the Company's consolidated VIEs totaling $701.1 million and $540.8 million as of September 30, 2024 and December 31, 2023, respectively, and total liabilities of the Company's consolidated VIEs for which creditors do not have recourse to the general credit of the primary beneficiary of $194.1 million and $146.0 million as of September 30, 2024 and December 31, 2023, respectively. These VIE balances do not include $413.3 million of investment in affiliates and $76.3 million of amounts due to affiliates as of September 30, 2024, and $273.2 million of investment in affiliates and $107.3 million of amounts due to affiliates as of December 31, 2023, as these are eliminated upon consolidation and not presented within the condensed consolidated balance sheets.

 

ASTRANA HEALTH, INC.

CONSOLIDATED STATEMENTS OF INCOME

(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)

(UNAUDITED)




Three Months Ended
September 30,



Nine Months Ended
September 30,




2024



2023



2024



2023


Revenue













Capitation, net


$

431,401



$

305,678



$

1,239,885



$

906,430


Risk pool settlements and incentives



21,779




15,022




57,564




48,605


Management fee income



2,747




9,898




8,429




32,287


Fee-for-service, net



18,692




15,892




54,588




41,216


Other revenue



4,091




1,683




8,865




5,087















Total revenue



478,710




348,173




1,369,331




1,033,625















Operating expenses













Cost of services, excluding depreciation and amortization



405,218




275,375




1,148,422




857,648


General and administrative expenses



37,803




29,410




112,478




74,648


Depreciation and amortization



7,264




4,305




19,801




12,846















Total expenses



450,285




309,090




1,280,701




945,142















Income from operations



28,425




39,083




88,630




88,483















Other income (expense)













Income (loss) from equity method investments



1,353




(2,104)




2,887




3,104


Interest expense



(8,856)




(3,779)




(25,028)




(10,680)


Interest income



3,778




3,281




11,287




9,617


Unrealized (loss) gain on investments



(561)




(342)




415




(5,875)


Other income



2,673




1,876




4,522




4,265















Total other (expense) income, net



(1,613)




(1,068)




(5,917)




431















Income before provision for income taxes



26,812




38,015




82,713




88,914















Provision for income taxes



7,831




10,042




25,004




30,971















Net income



18,981




27,973




57,709




57,943















Net income attributable to non-controlling interest



2,887




5,914




7,609




9,582















Net income attributable to Astrana Health, Inc.


$

16,094



$

22,059



$

50,100



$

48,361















Earnings per share – basic


$

0.34



$

0.47



$

1.05



$

1.04















Earnings per share – diluted


$

0.33



$

0.47



$

1.04



$

1.03


EBITDA

Set forth below are reconciliations of Net Income to EBITDA and Adjusted EBITDA as well as the reconciliation to Adjusted EBITDA margin for the three and nine months ended September 30, 2024 and 2023. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.



Three Months Ended
September 30,




Nine Months Ended
September 30,



(in thousands)


2024




2023




2024




2023



Net income


$

18,981




$

27,973




$

57,709




$

57,943



Interest expense



8,856





3,779





25,028





10,680



Interest income



(3,778)





(3,281)





(11,287)





(9,617)



Provision for income taxes



7,831





10,042





25,004





30,971



Depreciation and amortization



7,264





4,305





19,801





12,846



EBITDA



39,154





42,818





116,255





102,823




















(Income) loss from equity method investments



(1,353)





2,016





(2,887)





(3,160)



Other, net



1,206


(1)



1,723


(2)



2,663


(3)



1,507


(2)

Stock-based compensation



6,163





5,706





19,301





13,364



APC excluded asset costs



—





(289)





—





3,039



Adjusted EBITDA


$

45,170




$

51,974




$

135,332




$

117,573




















Total revenue


$

478,710




$

348,173




$

1,369,331




$

1,033,625




















Adjusted EBITDA margin



9

%




15

%




10

%




11

%


(1)

Other, net for the three months ended September 30, 2024 relates to non-cash changes related to change in the fair value of our financing obligation to purchase the remaining equity interests in one of our investments, non-cash changes related to change in the fair value of the Company's Collar Agreement, non-cash gain on debt extinguishment related to one of our promissory note payables, and transaction costs incurred for our investments and tax restructuring fees.



(2)

Other, net for the three and nine months ended September 30, 2023 relates to transaction costs incurred for our investments and tax restructuring fees and non-cash changes related to change in the fair value of our financing obligation to purchase the remaining equity interests, changes in the fair value of our contingent liabilities, and changes in the fair value of the Company's Collar Agreement.



(3)

Other, net for the nine months ended September 30, 2024 relates to financial guarantee via a letter of credit that we provided almost three years ago in support of two local provider-led ACOs, non-cash changes related to change in the fair value of our financing obligation to purchase the remaining equity interests in one of our investments, non-cash changes related to change in the fair value of the Company's Collar Agreement, non-cash gain on debt extinguishment related to one of our promissory note payables, transaction costs incurred for our investments and tax restructuring fees, and reimbursement from a related party of the Company for taxes associated with the Excluded Assets spin-off.

 

Guidance Reconciliation of Net Income to EBITDA and Adjusted EBITDA




2024 Guidance Range


(in thousands)


Low



High


Net income


$

59,340



$

66,240


Interest expense



18,750




18,750


Provision for income taxes



26,660




29,760


Depreciation and amortization



27,500




27,500


EBITDA



132,250




142,250









Income from equity method investments



(4,250)




(4,250)


Other, net



5,000




5,000


Stock-based compensation



32,000




32,000


Adjusted EBITDA


$

165,000



$

175,000


Use of Non-GAAP Financial Measures

This press release contains the non-GAAP financial measures EBITDA and Adjusted EBITDA, of which the most directly comparable financial measure presented in accordance with U.S. generally accepted accounting principles ("GAAP") is net income. These measures are not in accordance with, or alternatives to GAAP, and may be calculated differently from similar non-GAAP financial measures used by other companies. The Company uses Adjusted EBITDA as a supplemental performance measure of our operations, for financial and operational decision-making, and as a supplemental means of evaluating period-to-period comparisons on a consistent basis. Adjusted EBITDA is calculated as earnings before interest, taxes, depreciation, and amortization, excluding income or loss from equity method investments, non-recurring and non-cash transactions, stock-based compensation, and APC excluded assets costs. The Company defines Adjusted EBITDA margin as Adjusted EBITDA over total revenue.

The Company believes the presentation of these non-GAAP financial measures provides investors with relevant and useful information, as it allows investors to evaluate the operating performance of the business activities without having to account for differences recognized because of non-core or non-recurring financial information. When GAAP financial measures are viewed in conjunction with non-GAAP financial measures, investors are provided with a more meaningful understanding of the Company's ongoing operating performance. In addition, these non-GAAP financial measures are among those indicators the Company uses as a basis for evaluating operational performance, allocating resources, and planning and forecasting future periods. Non-GAAP financial measures are not intended to be considered in isolation, or as a substitute for, GAAP financial measures. Other companies may calculate both EBITDA and Adjusted EBITDA differently, limiting the usefulness of these measures for comparative purposes. To the extent this release contains historical or future non-GAAP financial measures, the Company has provided corresponding GAAP financial measures for comparative purposes. The reconciliation between certain GAAP and non-GAAP measures is provided above.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/astrana-health-inc-reports-third-quarter-2024-results-302299386.html

SOURCE Astrana Health, Inc.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

PRNewswire, Press Releases

Related Entities

Dividend, Earnings, Definitive Agreement